Erasca Faces Class Action Lawsuit Over Misleading Statements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: Globenewswire
Erasca Inc. saw its stock price rise by 8.36% and reach a 20-day high despite the broader market decline, with the Nasdaq-100 down 1.06% and the S&P 500 down 0.16%.
The recent class action lawsuits filed against Erasca allege that the company made false and misleading statements regarding its drug candidate ERAS-0015's preclinical data, which has raised significant concerns among investors. These lawsuits, initiated by multiple law firms, highlight the potential for substantial investor losses due to alleged patent and trade secret violations. The legal actions have prompted affected investors to seek representation, with deadlines approaching for lead plaintiff applications.
The implications of these lawsuits could be profound for Erasca, as they not only threaten the company's reputation but also its financial stability. Investors are advised to stay informed about the developments in these legal proceedings, as they may impact stock performance in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 14.950
Low
2.00
Averages
5.50
High
11.00
Current: 14.950
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Class Action Lawsuit Notice for Investors
- Class Action Deadline: Investors in Erasca, Inc. should note that the deadline to apply as lead plaintiff is August 10, 2026, and those who purchased shares between January 14, 2025, and April 26, 2026, may be entitled to compensation.
- Lawsuit Background: The lawsuit alleges that Erasca and its CEO and CFO violated federal securities laws by making false and misleading statements about their lead oncology drug candidate, ERAS-0015, resulting in investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first for the number of securities class action settlements in 2017, showcasing its strong reputation in this field.
- Investor Action Steps: Investors can visit the Rosen Law Firm's website or call toll-free for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Erasca Securities Fraud Class Action Reminder
- Lawsuit Background: Erasca, Inc. faces a class action lawsuit for allegedly making false statements regarding its lead oncology drug ERAS-0015 during the period from January 14, 2025, to April 26, 2026, failing to disclose patent and trade secret disputes that could lead to investor losses.
- Stock Price Volatility: On April 27, 2026, Erasca's stock price dropped by $2.34, approximately 11%, from $21.49 to $19.15, following a patent infringement allegation from competitor RevMed, indicating market concerns about the company's future prospects.
- Clinical Data Disclosure: On the same day, Erasca reported that a patient treated with ERAS-0015 died about a month after starting the treatment, causing the stock to plummet by $9.25, or about 48%, closing at $9.90, reflecting serious investor concerns over drug safety.
- Investor Action Recommendation: Investors must apply to be lead plaintiffs by August 10, 2026, to represent other affected parties in the lawsuit, as courts typically appoint individual investors as lead plaintiffs, underscoring the importance of investor participation in legal proceedings.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement by Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws that could lead to further investor losses.
- Safety Concerns Raised: The ERAS-0015 product is under scrutiny due to improper comparisons with competitor products, and the death of a patient one month post-treatment raises significant safety concerns, potentially impacting future clinical trials and market acceptance.
- Intellectual Property Dispute: Following the disclosure of a legal letter from Revolution Medicines challenging the validity of its intellectual property claims, Erasca may need to reassess its competitive position in the highly contested cancer treatment market, which could undermine investor confidence and necessitate strategic adjustments.
See More
Erasca Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Erasca in the Southern District of California on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, to apply as lead plaintiff.
- Allegations of Misrepresentation: The lawsuit alleges that Erasca and its executives made false and misleading statements regarding ERAS-0015's preclinical data, failing to disclose significant adverse facts related to patent and trade secret violations, which has led to substantial investor losses.
- Stock Price Plummet: Following the April 28, 2026 disclosure of potential patent infringement by Revolution Medicines, Erasca's stock price fell from $19.15 on April 27, 2026, to $9.90, representing a 48% decline that directly impacted investor asset values.
- Legal Consultation Available: Affected investors are encouraged to contact Bragar Eagel & Squire via email or phone to discuss their legal rights and potential claims, with no fees for the consultation process.
See More
Erasca Faces Class Action Lawsuit from Investors Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Erasca, Inc. to recover damages for investors who purchased securities between January 14, 2025, and April 26, 2026, reflecting strong investor response to potential violations by the company.
- Allegations of False Statements: The complaint alleges that Erasca made false and misleading statements during the class period, failing to disclose that ERAS-0015's preclinical data was based on improper comparisons, which could jeopardize patent and trade secret protections, thereby impacting investor confidence.
- Investor Action Deadline: Affected investors have until August 10, 2026, to request to be appointed as lead plaintiff, indicating the importance of legal proceedings in protecting investor rights and interests.
- No-Cost Representation: The law firm operates on a contingency fee basis, meaning they only charge fees if they successfully recover damages, which reduces the financial burden on investors and encourages their participation in the lawsuit.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS), encouraging those who purchased shares during the class period from January 14, 2025, to April 26, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose that ERAS-0015's preclinical data was improperly compared to Revolution Medicines, Inc., risking patent and trade secret violations for Erasca.
- Lead Plaintiff Deadline: The deadline for shareholders to seek lead plaintiff status is August 10, 2026, and they are urged to register promptly to participate in the class action, with portfolio monitoring software provided for case status updates.
- Law Firm Credentials: The Gross Law Firm is a nationally recognized class action law firm committed to protecting the rights of investors who have suffered losses due to deceit and illegal business practices, ensuring companies adhere to responsible business conduct.
See More
Erasca Class Action Lawsuit Notice for Investors
- Class Action Deadline: Investors in Erasca, Inc. should note that the deadline to apply as lead plaintiff is August 10, 2026, and those who purchased shares between January 14, 2025, and April 26, 2026, may be entitled to compensation.
- Lawsuit Background: The lawsuit alleges that Erasca and its CEO and CFO violated federal securities laws by making false and misleading statements about their lead oncology drug candidate, ERAS-0015, resulting in investor losses when the truth emerged.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first for the number of securities class action settlements in 2017, showcasing its strong reputation in this field.
- Investor Action Steps: Investors can visit the Rosen Law Firm's website or call toll-free for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Erasca Securities Fraud Class Action Reminder
- Lawsuit Background: Erasca, Inc. faces a class action lawsuit for allegedly making false statements regarding its lead oncology drug ERAS-0015 during the period from January 14, 2025, to April 26, 2026, failing to disclose patent and trade secret disputes that could lead to investor losses.
- Stock Price Volatility: On April 27, 2026, Erasca's stock price dropped by $2.34, approximately 11%, from $21.49 to $19.15, following a patent infringement allegation from competitor RevMed, indicating market concerns about the company's future prospects.
- Clinical Data Disclosure: On the same day, Erasca reported that a patient treated with ERAS-0015 died about a month after starting the treatment, causing the stock to plummet by $9.25, or about 48%, closing at $9.90, reflecting serious investor concerns over drug safety.
- Investor Action Recommendation: Investors must apply to be lead plaintiffs by August 10, 2026, to represent other affected parties in the lawsuit, as courts typically appoint individual investors as lead plaintiffs, underscoring the importance of investor participation in legal proceedings.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement by Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws that could lead to further investor losses.
- Safety Concerns Raised: The ERAS-0015 product is under scrutiny due to improper comparisons with competitor products, and the death of a patient one month post-treatment raises significant safety concerns, potentially impacting future clinical trials and market acceptance.
- Intellectual Property Dispute: Following the disclosure of a legal letter from Revolution Medicines challenging the validity of its intellectual property claims, Erasca may need to reassess its competitive position in the highly contested cancer treatment market, which could undermine investor confidence and necessitate strategic adjustments.
See More
Erasca Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Erasca in the Southern District of California on behalf of investors who purchased shares between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, to apply as lead plaintiff.
- Allegations of Misrepresentation: The lawsuit alleges that Erasca and its executives made false and misleading statements regarding ERAS-0015's preclinical data, failing to disclose significant adverse facts related to patent and trade secret violations, which has led to substantial investor losses.
- Stock Price Plummet: Following the April 28, 2026 disclosure of potential patent infringement by Revolution Medicines, Erasca's stock price fell from $19.15 on April 27, 2026, to $9.90, representing a 48% decline that directly impacted investor asset values.
- Legal Consultation Available: Affected investors are encouraged to contact Bragar Eagel & Squire via email or phone to discuss their legal rights and potential claims, with no fees for the consultation process.
See More
Erasca Faces Class Action Lawsuit from Investors Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Erasca, Inc. to recover damages for investors who purchased securities between January 14, 2025, and April 26, 2026, reflecting strong investor response to potential violations by the company.
- Allegations of False Statements: The complaint alleges that Erasca made false and misleading statements during the class period, failing to disclose that ERAS-0015's preclinical data was based on improper comparisons, which could jeopardize patent and trade secret protections, thereby impacting investor confidence.
- Investor Action Deadline: Affected investors have until August 10, 2026, to request to be appointed as lead plaintiff, indicating the importance of legal proceedings in protecting investor rights and interests.
- No-Cost Representation: The law firm operates on a contingency fee basis, meaning they only charge fees if they successfully recover damages, which reduces the financial burden on investors and encourages their participation in the lawsuit.
See More
Erasca Shareholder Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ: ERAS), encouraging those who purchased shares during the class period from January 14, 2025, to April 26, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose that ERAS-0015's preclinical data was improperly compared to Revolution Medicines, Inc., risking patent and trade secret violations for Erasca.
- Lead Plaintiff Deadline: The deadline for shareholders to seek lead plaintiff status is August 10, 2026, and they are urged to register promptly to participate in the class action, with portfolio monitoring software provided for case status updates.
- Law Firm Credentials: The Gross Law Firm is a nationally recognized class action law firm committed to protecting the rights of investors who have suffered losses due to deceit and illegal business practices, ensuring companies adhere to responsible business conduct.
See More
